Cantor Fitzgerald Issues Positive Outlook for PTCT Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Equities research analysts at Cantor Fitzgerald upped their FY2025 earnings per share estimates for PTC Therapeutics in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will earn ($2.74) per share for the year, up from their previous estimate of ($3.26). Cantor Fitzgerald has a “Overweight” rating and a $113.00 price target on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share.

Other research analysts have also issued reports about the stock. JPMorgan Chase & Co. lowered their price objective on shares of PTC Therapeutics from $74.00 to $72.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Barclays boosted their price target on PTC Therapeutics from $45.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 3rd. Morgan Stanley upgraded PTC Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $45.00 to $67.00 in a research note on Friday, December 13th. StockNews.com lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Robert W. Baird raised their price target on PTC Therapeutics from $52.00 to $70.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Three research analysts have rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, PTC Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $62.08.

PTC Therapeutics Trading Up 1.7 %

NASDAQ PTCT opened at $52.80 on Thursday. The firm has a market capitalization of $4.07 billion, a P/E ratio of -8.89 and a beta of 0.62. The firm’s fifty day moving average price is $47.71 and its two-hundred day moving average price is $42.72. PTC Therapeutics has a 1 year low of $24.00 and a 1 year high of $55.60.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PTCT. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of PTC Therapeutics in the 4th quarter valued at $4,891,000. Mackenzie Financial Corp boosted its stake in PTC Therapeutics by 132.2% in the fourth quarter. Mackenzie Financial Corp now owns 22,776 shares of the biopharmaceutical company’s stock valued at $1,028,000 after buying an additional 12,967 shares in the last quarter. Toronto Dominion Bank acquired a new stake in PTC Therapeutics in the fourth quarter valued at about $148,363,000. GF Fund Management CO. LTD. bought a new position in PTC Therapeutics in the fourth quarter valued at about $73,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in PTC Therapeutics by 19.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 160,251 shares of the biopharmaceutical company’s stock worth $7,234,000 after acquiring an additional 26,274 shares in the last quarter.

Insiders Place Their Bets

In other PTC Therapeutics news, CAO Christine Marie Utter sold 1,291 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $45.34, for a total value of $58,533.94. Following the transaction, the chief accounting officer now directly owns 65,983 shares of the company’s stock, valued at $2,991,669.22. This trade represents a 1.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Lee Scott Golden sold 795 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total transaction of $39,829.50. Following the completion of the transaction, the executive vice president now owns 77,856 shares of the company’s stock, valued at $3,900,585.60. The trade was a 1.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,870 shares of company stock worth $1,075,657 in the last quarter. 5.50% of the stock is currently owned by corporate insiders.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.